SignatureFD’s MiNK Therapeutics INKT Stock Holding History

SignatureFD’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1	Closed	-$14	–	3218
2023 Q4	$14	Sell	1 -1	-50%	-$10	﹤0.01%	3109
2023 Q3	$20	Sell	2 -4	-67%	-$65	﹤0.01%	3170
2023 Q2	$134	Buy	+6	New	+$120	﹤0.01%	3166

Other funds holding INKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SignatureFD's INKT Position: Q1 2024 in Review

SignatureFD sold out of MiNK Therapeutics (INKT) in Q1 2024, closing a stake of 1 share — an estimated $14 sold.

SignatureFD first reported a position in INKT in Q2 2023 and held it in 3 quarters. The position peaked at $134 in Q2 2023. 33 funds tracked by Wall St. Rank hold INKT as of Q1 2024.

SignatureFD reported no remaining MiNK Therapeutics position as of Q1 2024 after selling out during the quarter.
SignatureFD sold 1 MiNK Therapeutics share in Q1 2024, an estimated $14.
SignatureFD first reported a position in MiNK Therapeutics in Q2 2023 and held it in 3 quarters.
SignatureFD's MiNK Therapeutics position peaked at $134 in Q2 2023.
33 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2024.

Based on SignatureFD's 13F filing for Q1 2024, filed 3 May 2024.